Nolva with 19nors. Whats the TRUTH?

[RJ]

For some reason over the last year or so, all i have seen on this board (as I don't visit others) is how devastating it is to use Tamoxifen with 19nors. Now, before we get into this, I don't wanna hear a bunch of parroted shit from people who have no experience with it. I have used Tamoxifen personally while using Deca and Tren and had no issues with the supposed problems that have said to arisen in the past year or so. I have also done loads of reading on it. So lets have a healthy debate shall we? Humdiddly, feel free to use all the big words you like... as long as I understand them. lol

Now, here is what my research tells me. Tamoxifen is a mixed ER agonist/antagonist.

In some tissues, such as the endometrium (uterus), upregulation of the progesterone receptor would be expected, as the endometrium is very sensitive to estrogen. This is where i believe there is confusion.

In other tissues, such as the breast, Tamoxifen is an antagonist (blocks the ER). The progesterone receptor is synthesized in response to estrogen. So when the ER is blocked (in breast tissue), the progesterone receptor will also down regulate. This is what happens in cancer patients and we're no different.

Therefore, Tamoxifen will help reduce gyno even when using Tren or Deca, not make it worse.

Now, Tamoxifen will down regulate the progesterone receptor in breast tissue. Some "guru's" state Tamoxifen will up regulate the progesterone receptor and cause or lead to gyno. By either worsening estrogenic gyno or by itself. They, therefore, assume Tamoxifen CANT be used with Deca or Tren, but this is false.

Now, some of you may be confused about gyno. Maybe this will help.

You can get gyno (it seems) 3 ways. First off, from estrogen. Second, from progesterone alone, or progesterone making estrogenic gyno worse. And finally, from prolactin.

Tamoxifen can be used to treat gyno from either Deca or Tren, whether it be from estrogen or progesterone. BUT Tamoxifen CANNOT treat prolactin induced gyno. But can treat estrogenic gyno or progestenic gyno (if that exists).

Deca and Tren will both elevate PRL (Prolactin) levels (although, again debatable). Therefore, for PRL related sides, such as loss of libido, gyno and lactation (although not only from PRL), Caber, Prami or Dostinex need to be used.

You see, when people use Deca and Tren, they tend to use Testosterone too. So if they experienced gyno, it may be from estrogen, NOT from Deca and Tren and again, thus being OK to use Tamoxifen.

Basically, as progesterone is synthesised in response to estrogen, if you control estrogen, you essentially reduce progesterone sides as well.

I hope that clears some confusion because you will NOT find a study stating Tamoxifen up regulates the progesterone receptor in breast tissue anywhere. I have never seen a case of gyno solely caused by PgR. It just seems impossible as the PgR is synthesized by the ER (Estrogen Receptor).

This is from bigcat's steroid profiles, which summarizes some of the above about nolvadex and 19-nor:

"If indeed the overall yield of estrogen is so much smaller, and so is the rate of androgen receptor stimulation, how then is nandrolone so anabolic? The common belief is through a third receptor : the progesterone receptor. It has been concluded that both nandrolone2 and several of its metabolites3,4 do indeed activate the progesterone receptor and are altered by it. On the one hand progestagenic activity decreases the estrogen receptor concentration in some tissues, it also mediates estrogenic action in other tissues5. So while estrogenic side-effects are fairly uncommon with nandrolone use alone, they can indeed occur and the implications of nandrolone's activity as a progesterone indicate these potential side-effects aren't to be solved with an aromatase inhibitor alone (like Cytadren). As long as there is estrogen in the system (indicating a possible increase of the problem when stacked with another aromatizing compound) progesterone can agonize its effects. And since progesterone receptors are found in breast tissue and have been linked to the formation of milk ducts, progestagenic activity may aggravate possibly gynocomastia. So while such problems are rare, when they occur they aren't easily treated.

It makes sense then that those particularly prone to the effects and side-effects of estrogen would take extra precaution. Blocking aromatase, considering the previous paragraph, would be a poor choice, but competitively inhibiting the estrogen receptor itself with clomiphene citrate (Clomid) or tamoxifen citrate (Nolvadex) might bring some relief since a large portion of progestagenic action is nullified if there is no circulating estrogen around, or if it is kept from being activated by the estrogen receptor."

One last thing. This thread is not meant to sway anyone from using or not using Tamoxifen with 19nors. Some of you may get worse sides from adding Nolva to a Deca or Tren laden cycle, but saying everyone will is misinformation.

As I have said a bilion times, everyone is different. For example, at the end of my cycling days all I took ever was a small amount of Aromasin. And I don't get gyno from even 1g of test a week. But that's me. I have just gotten a little peeved at seeing everyone say DON"T USE NOLVADEX WITH 19NORS OR IT WILL CAUSE PROBLEMS.

Use should always be conducted following thorough research and then through trial and error. Yes, knowledge from others is great as a start, but you have to find out what works for YOU and only YOU!!!!!

 

[cyto33]

i am guilty of saying dont dont dont when it come to using Nolva and nor19s
this is what i feel is right FOR ME and passing this off to others they need to remember this is only advice form what works for them. it may not work for other so do your own research.
i have always been told never do 2 nor19s at the same time.
well i have and for me unlike RJ i had a flare up very sore nipples with lumps under neath.
big deal i will treat it after.

Bu this is some of the info i have read in the past from diffrent boards and has found its way here.
heres the link. http://www.steroidology.com/forum/a...esearching-link-between-19-nors-nolvadex.html

 

[CenturionHRT]

I agree other then for progesterone causing gyno by itself. From what I've found through research is that progesterone needs estrogen to cause gyno.

I think that some of the confusion comes from people thinking that prolactin gyno/leaky nips is caused by progesterone and not prolactin.

Taking Nolva could actually increase prolactin levels since it does not eliminate estrogen but simply blocks it and in some cases can actually raise total estrogen levels in the body. High levels of estrogen can raise overall prolactin levels.

So if you are having prolactin issues such as leaky nips, ED or problems busting a nut. Nolva in these situations will not help but could further raise prolactin levels.

Although you could use both an Aromatase inhibitor (AI) and Nolva and not have to worry about it while using deca or during pct.

 

[RJ]

I agree other then for progesterone causing gyno by itself. From what I've found through research is that progesterone needs estrogen to cause gyno.

I think that some of the confusion comes from people thinking that prolactin gyno/leaky nips is caused by progesterone and not prolactin.

Taking Nolva could actually increase prolactin levels since it does not eliminate estrogen but simply blocks it and in some cases can actually raise total estrogen levels in the body. High levels of estrogen can raise overall prolactin levels.

So if you are having prolactin issues such as leaky nips, ED or problems busting a nut. Nolva in these situations will not help but could further raise prolactin levels.

Although you could use both an Aromatase inhibitor (AI) and Nolva and not have to worry about it while using deca or during pct.

very good points boys. I like this thread so far. lol

 

[THE-DET-OAK]

You know im with you on this one RJ, you got me fishing around for the truth on this a while ago.

Basically what i have found, is that the whole thing started with the study in Cyto's link saying the it up regulated the PGR. Well it did, but that was in the endometrial tissue of a uterus. So basically you cant draw the conclusion that it WILL happen in the breast tissue of a man. Nolva acts like an estrogen in some tissues, and like and anti-e in some tissues.

So i believed it was bullshit for some time.

Ive talked with Bill Roberts on the subject and he says most of the time, Nolva should work fine for Gyno with 19-nors.

On the other hand, i have seen medical studies stating that it can do either, and they dont know why, it may up-reg PGR or it may Down-reg PGR.

I think the factors of what it will do are unkown, but so far i like centurion rationale and yours because it will be different for everyone.

 

[1badmofo]

I'm not arguing either way, but RJH from some of your post(if I recall correctly) it sounds like you are lucky to not get many sides like some guys do, and if you do then obviously you know how to control them.

 

[Teutonic]

good one rjh..I m quilty of regurgetating what I ve read...
P S you look good...real good...real hard and full..this old man s gonna have to step it up this winter to catch up..I need the motivation..
We should all post up an avi..if pinga does not get upset bout the skin hahaha
your hard work shows..
T

 

[Mr. Humdiddly]

On preliminary analysis this post fosters a cognitive response. RJ, may I add a treatise of my own to this thread?

 

[CenturionHRT]

good one rjh..I m quilty of regurgetating what I ve read...
P S you look good...real good...real hard and full..this old man s gonna have to step it up this winter to catch up..I need the motivation..
We should all post up an avi..if pinga does not get upset bout the skin hahaha
your hard work shows..
T

I think we are are guilty of this Teutonic... I am at least. There are many finely wrote articles out there by self titled "anabolic experts". When one of these articles hit the web it goes viral and we all start to believe it word for word.

Don't get me wrong some of these articles actually have good information in them. Some dont we just need to do some research for ourselves,actually check their sources, read between the lines and see beyond the bullshit like RJH90210 has.

 

[CenturionHRT]

On preliminary analysis this post fosters a cognitive response. RJ, may I add a treatise of my own to this thread?

I say give it Humdiddly! Your posts are always well thought out and provide some good insight. I look forward to reading your feedback on this subject.

 

[RJ]

On preliminary analysis this post fosters a cognitive response. RJ, may I add a treatise of my own to this thread?

of course. thats why i started the thread.

again, this wasn't meant to sway anyone,just to give some solid logic to the typical stuff we hear regurgitated on the boards all the time.

 

[RJ]

Don't get me wrong some of these articles actually have good information in them. Some dont we just need to do some research for ourselves,actually check their sources, read between the lines and see beyond the bullshit like RJH90210 has.

this is EXACTLY why i wrote this thread. great post

 

[557mustang]

I just gave up on nolva all together when I read some stuff about the upregulating. So I'm very interested in seeing some more opinions here...

 

[Mr. Humdiddly]

With regards to the study performed on endometrial tissue I have realized that there is a major disparity in the the information relayed. The case in point was actually performed by two physicians, Dr. Pérez-López FR, and Dr. Blasco Comenge C. in 1993. The title of the study was

"Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast."
Published in Gynecological Endocrinology Magazine (See references).

At some point in time someone read this then came up with a false summation regarding Tamoxifen upregulatation of progesterone receptors. This falsity was then spread about and became a universal truth. Tamoxifen does in fact upregulate pregesterone receptors (PGR) in some individuals as I will explain later, however the Lopez-Comenge trial found that tamoxifen had no effect on progesterone receptors in endometrial tissue at all. That means no upregulation nor any down regulation.

This concept should have been apparent to many from the start as Nolvadex has a strong affinity to receptors in the pectoral region. Hence it's once famous usage tout regarding gynecomastia prevention. As a result of this affinity Nolvadex has very little effect on tissues outside of the pectoral region. I have provided the abstract as a reference point.

Most online medical journal sites have a copy of the entirety of the clinical trials, but for the purposes of this treatise we are concerned with end results thus a abstract proves a suitable alternative since most of you are not willing to pay a subscription fee to view medical trials (though I urge you to start).

I have taken the liberty of emphasizing the key point.

Abstract

Endocrine changes were determined after a 3-week cycle of tamoxifen treatment in 11 regularly cycling women with clinical and radiological evidence of fibrocystic disease of the breast. Blood and endometrial samples were obtained during the luteal phase prior to and at the end of treatment. Tamoxifen treatment (20 mg/day orally for 3 weeks), produced a significant increase in plasma estradiol (p = 0.0018) without simultaneous changes in plasma luteinizing hormone, follicle stimulating hormone, prolactin or progesterone. Tamoxifen treatment significantly reduced endometrial estrogen receptor levels compared to the control cycle (p = 0.0018) while endometrial progesterone receptor levels remained unchanged. Endometrial histological studies showed secretory transformation in both the control cycle and after tamoxifen treatment. The reduction in endometrial estrogen receptor concentrations would suggest a tamoxifen-induced effect or a down-regulatory mechanism to protect target tissues from high estradiol levels. These changes were not associated with alterations in either plasma progesterone or endometrial progesterone receptor concentrations. The tamoxifen-induced changes did not produce any interference in the glandular secretory response of the endometrium.

So that is one myth dispelled. Tamoxifen has no effect on receptors other than those found in the pectoral region. So the endometrial progesterone receptor upregulation story is a myth.


Proceeding to the pectoral region of the body we do notice a different story. In the long run Tamoxifen down regulates both progesterone and estrogen receptors. I know this is contrary to popular belief but note I said in the long run meaning 3-4 weeks. A study was done by Dr. N Waseda, Dr. Y Kato, Dr. H Imura, and Dr. M Kurata. The title of the article was:

"Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer."
Published in Cancer Research Magazine (See references)

The results showed that use of tamoxifen during the first two weeks actually did in fact upregulate both estrogen and progesterone receptors. This may seem counter-intuitive to some of you. Your probably thinking. "Wait, if tamoxifen actually upregulates estrogen receptors then why is it used for gynecomastia prevention?" The key element here is that tamoxifen is a SERM. Tamoxifen may upregulate estrogen receptor sites but, it also binds them.

Tamoxifen cannot bind to progesterone receptors though. So in the short run Tamoxifen can in fact aggravate progesterone related gynecomastia for some individuals. Note the study utilized twenty individuals and only 3 out of 5 (60%) had PGR upregulation. In the span of 3-4 weeks those same patients with increased PGR noticed a decrease in PGR levels.

So in summation, in the short run I.E. a span of 1-2 weeks approximately 60% of people will experience progesterone upregulation. In the long run however, EVERYONE will experience PGR downregulation.

So what's my recommendation? Implement Tamoxifen use 4 weeks prior to a 19-nor cycle to down regulate PGR receptors. Of course this whole treatise is a moot point as the use of a prolactin inhibitors makes progesterone gynecomastia a thing of the past.

Once again I have provided the abstract and highlighted key points.

Abstract

Twenty patients with primary breast cancer were treated with tamoxifen (10 mg p.o. twice a day) for 1 to 4 weeks. Before and after the tamoxifen administration, tumor specimens were obtained and assayed for estrogen receptors and progesterone receptors (PGR). Total cytosol estrogen receptor (ERC) and occupied nuclear estrogen receptor (ERN) were measured by hydroxylapatite assay, and unoccupied PGR was measured by the dextran-coated charcoal assay. ERC, ERN, and PGR were detectable in 11, 8, and 6 tumors, respectively, before tamoxifen administration. After tamoxifen treatment, ERC decreased in 10 of 11 ERC-positive tumors. Occupied ERN increased in three of five ERN-positive tumors treated with tamoxifen for a short period (1 to 2 weeks), but they decreased in all of three ERN-positive tumors after longer administration (3 to 4 weeks). PGR increased in three of five ERN-positive tumors after short-term tamoxifen treatment, but they decreased in all of three tumors treated by the drug for a longer period. Increased PGR responses were accompanied by an increase of ERN in two of three ERN-positive tumors. These results suggest that tamoxifen interacts with the estrogen receptor system in human breast cancer tissue and may be estrogenic during short treatment, while longer treatment results in an antiestrogenic response.

I of course have several more sources regarding this matter I put the two referenced and two others in my references. I have a total of 31 articles related to this though and I am too lazy to put them all in. If you have questions regarding certain topics I can point you towards an article that may clarify the topic for you.


References
1. Gynecol Endocrinol. 1993 Sep;7(3):185-9. Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Pérez-López FR, Blasco Comenge C. Department of Obstetrics and Gynecology, Hospital Clínico, Zaragoza, Spain.

2. Cancer Res. 1981 May;41(5):1984-8.
Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Waseda N, Kato Y, Imura H, Kurata M.

3. Br J Cancer. 1993 March; 67(3): 606–611. PMCID: PMC1968274
Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. R. B. Clarke, I. J. Laidlaw, L. J. Jones, A. Howell, and E. Anderson
Clinical Research Dept., Christie Hospital NHS Trust, Withington, Manchester.

4. Clinical Cancer Research. High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Maria Stendahl1,2, Lisa Rydén1, Bo Nordenskjöld3, Per Ebbe Jönsson4, Göran Landberg1 and Karin Jirström1

 

[Mr P]

 

[Mr. Humdiddly]

This may be the closest thing to collaboration between RJ and myself ever.

 

[Italiano SPO]

With regards to the study performed on endometrial tissue I have realized that there is a major disparity in the the information relayed. The case in point was actually performed by two physicians, Dr. Pérez-López FR, and Dr. Blasco Comenge C. in 1993. The title of the study was

"Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast."
Published in Gynecological Endocrinology Magazine (See references).

At some point in time someone read this then came up with a false summation regarding Tamoxifen upregulatation of progesterone receptors. This falsity was then spread about and became a universal truth. Tamoxifen does in fact upregulate pregesterone receptors (PGR) in some individuals as I will explain later, however the Lopez-Comenge trial found that tamoxifen had no effect on progesterone receptors in endometrial tissue at all. That means no upregulation nor any down regulation.

This concept should have been apparent to many from the start as Nolvadex has a strong affinity to receptors in the pectoral region. Hence it's once famous usage tout regarding gynecomastia prevention. As a result of this affinity Nolvadex has very little effect on tissues outside of the pectoral region. I have provided the abstract as a reference point.

Most online medical journal sites have a copy of the entirety of the clinical trials, but for the purposes of this treatise we are concerned with end results thus a abstract proves a suitable alternative since most of you are not willing to pay a subscription fee to view medical trials (though I urge you to start).

I have taken the liberty of emphasizing the key point.



So that is one myth dispelled. Tamoxifen has no effect on receptors other than those found in the pectoral region. So the endometrial progesterone receptor upregulation story is a myth.


Proceeding to the pectoral region of the body we do notice a different story. In the long run Tamoxifen down regulates both progesterone and estrogen receptors. I know this is contrary to popular belief but note I said in the long run meaning 3-4 weeks. A study was done by Dr. N Waseda, Dr. Y Kato, Dr. H Imura, and Dr. M Kurata. The title of the article was:

"Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer."
Published in Cancer Research Magazine (See references)

The results showed that use of tamoxifen during the first two weeks actually did in fact upregulate both estrogen and progesterone receptors. This may seem counter-intuitive to some of you. Your probably thinking. "Wait, if tamoxifen actually upregulates estrogen receptors then why is it used for gynecomastia prevention?" The key element here is that tamoxifen is a SERM. Tamoxifen may upregulate estrogen receptor sites but, it also binds them.

Tamoxifen cannot bind to progesterone receptors though. So in the short run Tamoxifen can in fact aggravate progesterone related gynecomastia for some individuals. Note the study utilized twenty individuals and only 3 out of 5 (60%) had PGR upregulation. In the span of 3-4 weeks those same patients with increased PGR noticed a decrease in PGR levels.

So in summation, in the short run I.E. a span of 1-2 weeks approximately 60% of people will experience progesterone upregulation. In the long run however, EVERYONE will experience PGR downregulation.

So what's my recommendation? Implement Tamoxifen use 4 weeks prior to a 19-nor cycle to down regulate PGR receptors. Of course this whole treatise is a moot point as the use of a prolactin inhibitors makes progesterone gynecomastia a thing of the past.

Once again I have provided the abstract and highlighted key points.



I of course have several more sources regarding this matter I put the two referenced and two others in my references. I have a total of 31 articles related to this though and I am too lazy to put them all in. If you have questions regarding certain topics I can point you towards an article that may clarify the topic for you.


References
1. Gynecol Endocrinol. 1993 Sep;7(3):185-9. Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Pérez-López FR, Blasco Comenge C. Department of Obstetrics and Gynecology, Hospital Clínico, Zaragoza, Spain.

2. Cancer Res. 1981 May;41(5):1984-8.
Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Waseda N, Kato Y, Imura H, Kurata M.

3. Br J Cancer. 1993 March; 67(3): 606–611. PMCID: PMC1968274
Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. R. B. Clarke, I. J. Laidlaw, L. J. Jones, A. Howell, and E. Anderson
Clinical Research Dept., Christie Hospital NHS Trust, Withington, Manchester.

4. Clinical Cancer Research. High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Maria Stendahl1,2, Lisa Rydén1, Bo Nordenskjöld3, Per Ebbe Jönsson4, Göran Landberg1 and Karin Jirström1

Thanks Mr H. Excellent post my friend!

 

[Italiano SPO]

With regards to the study performed on endometrial tissue I have realized that there is a major disparity in the the information relayed. The case in point was actually performed by two physicians, Dr. Pérez-López FR, and Dr. Blasco Comenge C. in 1993. The title of the study was

"Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast."
Published in Gynecological Endocrinology Magazine (See references).

At some point in time someone read this then came up with a false summation regarding Tamoxifen upregulatation of progesterone receptors. This falsity was then spread about and became a universal truth. Tamoxifen does in fact upregulate pregesterone receptors (PGR) in some individuals as I will explain later, however the Lopez-Comenge trial found that tamoxifen had no effect on progesterone receptors in endometrial tissue at all. That means no upregulation nor any down regulation.

This concept should have been apparent to many from the start as Nolvadex has a strong affinity to receptors in the pectoral region. Hence it's once famous usage tout regarding gynecomastia prevention. As a result of this affinity Nolvadex has very little effect on tissues outside of the pectoral region. I have provided the abstract as a reference point.

Most online medical journal sites have a copy of the entirety of the clinical trials, but for the purposes of this treatise we are concerned with end results thus a abstract proves a suitable alternative since most of you are not willing to pay a subscription fee to view medical trials (though I urge you to start).

I have taken the liberty of emphasizing the key point.



So that is one myth dispelled. Tamoxifen has no effect on receptors other than those found in the pectoral region. So the endometrial progesterone receptor upregulation story is a myth.


Proceeding to the pectoral region of the body we do notice a different story. In the long run Tamoxifen down regulates both progesterone and estrogen receptors. I know this is contrary to popular belief but note I said in the long run meaning 3-4 weeks. A study was done by Dr. N Waseda, Dr. Y Kato, Dr. H Imura, and Dr. M Kurata. The title of the article was:

"Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer."
Published in Cancer Research Magazine (See references)

The results showed that use of tamoxifen during the first two weeks actually did in fact upregulate both estrogen and progesterone receptors. This may seem counter-intuitive to some of you. Your probably thinking. "Wait, if tamoxifen actually upregulates estrogen receptors then why is it used for gynecomastia prevention?" The key element here is that tamoxifen is a SERM. Tamoxifen may upregulate estrogen receptor sites but, it also binds them.

Tamoxifen cannot bind to progesterone receptors though. So in the short run Tamoxifen can in fact aggravate progesterone related gynecomastia for some individuals. Note the study utilized twenty individuals and only 3 out of 5 (60%) had PGR upregulation. In the span of 3-4 weeks those same patients with increased PGR noticed a decrease in PGR levels.

So in summation, in the short run I.E. a span of 1-2 weeks approximately 60% of people will experience progesterone upregulation. In the long run however, EVERYONE will experience PGR downregulation.

So what's my recommendation? Implement Tamoxifen use 4 weeks prior to a 19-nor cycle to down regulate PGR receptors. Of course this whole treatise is a moot point as the use of a prolactin inhibitors makes progesterone gynecomastia a thing of the past.

Once again I have provided the abstract and highlighted key points.



I of course have several more sources regarding this matter I put the two referenced and two others in my references. I have a total of 31 articles related to this though and I am too lazy to put them all in. If you have questions regarding certain topics I can point you towards an article that may clarify the topic for you.


References
1. Gynecol Endocrinol. 1993 Sep;7(3):185-9. Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Pérez-López FR, Blasco Comenge C. Department of Obstetrics and Gynecology, Hospital Clínico, Zaragoza, Spain.

2. Cancer Res. 1981 May;41(5):1984-8.
Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Waseda N, Kato Y, Imura H, Kurata M.

3. Br J Cancer. 1993 March; 67(3): 606–611. PMCID: PMC1968274
Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. R. B. Clarke, I. J. Laidlaw, L. J. Jones, A. Howell, and E. Anderson
Clinical Research Dept., Christie Hospital NHS Trust, Withington, Manchester.

4. Clinical Cancer Research. High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Maria Stendahl1,2, Lisa Rydén1, Bo Nordenskjöld3, Per Ebbe Jönsson4, Göran Landberg1 and Karin Jirström1

This should be a sticky so the information doesn't have to be researched again and can be easily accessible.

 

[Mr. Humdiddly]

This should be a sticky so the information doesn't have to be researched again and can be easily accessible.

Maybe we can run it by Dadawg when he gets back. My interactions with the other mods are pretty limited. Pretty sure most of them have never heard of me.

 

[Italiano SPO]

Maybe we can run it by Dadawg when he gets back. My interactions with the other mods are pretty limited. Pretty sure most of them have never heard of me.

Good idea. This research was done by a pretty respected bro (Macro) some time ago but I was too lazy to try and find it. Thanks for posting and hopefully Dawg will put it up as a sticky.